MedTrace Logo

Ideal Time of Oxytocin Infusion During Cesarean Section

NCT03246919 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2020-06-18

No results posted yet for this study

Summary

This study will evaluate if the timing of oxytocin administration in cesarean deliveries will affect the amount of maternal blood loss. Half of participants will receive oxytocin after delivery of the fetal anterior shoulder and the other half will receive oxytocin after delivery of the placenta. We hypothesize that administering oxytocin after delivery of the shoulder, will result in less overall maternal blood loss.

Conditions

  • Blood Loss, Surgical
  • Postpartum Hemorrhage
  • Bleed Pregnancy
  • Pregnancy Related
  • Cesarean Section Complications

Interventions

DRUG

Oxytocin

Oxytocin is administered after delivery of the fetal anterior shoulder, rather than being administered after delivery of the placenta

DRUG

Placebo

Placebo will be administered after delivery of the placenta

Sponsors & Collaborators

  • Loyola University

    lead OTHER

Principal Investigators

  • Thaddeus Waters, MD · Loyola University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-13
Primary Completion
2020-02-24
Completion
2020-02-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03246919 on ClinicalTrials.gov